TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05957562

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EA/TOF primary repair with Azygos vein preservation
Description: primary repair of EA/TOF with either azygous vein preservation or disconnection (to assess the effects and expected benefits of the former technique on viability of the repair and decrease of postoperative early complications and mortality rate)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EA/TOF primary repair with Azygos vein sacrifice (disconnection)
Description: primary repair of EA/TOF with either azygous vein preservation or disconnection (to assess the effects and expected benefits of the former technique on viability of the repair and decrease of postoperative early complications and mortality rate)
Study: NCT02942407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apixaban
Description: oral anticoagulant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Description: oral anticoagulant
Study: NCT02061592

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A
Study: NCT02325453

Intervention type: PROCEDURE
Intervention: Robotic Surgery
Description: Surgical procedure performed with a robotic system.

Intervention type: PROCEDURE
Intervention: Laparoscopic Surgery
Description: Surgical procedure performed with laparoscopic techniques.

Intervention type: PROCEDURE
Intervention: Open Surgery
Description: Traditional approach for gastric cancer.
Study: NCT03324958

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality Helmet
Description: The virtual reality helmet will be installed by a radiotherapist or a radiotherapy manipulator, just before the intra vaginal applicator. The virtual reality headset will be connected to a dedicated computer. The virtual reality program will run for 10 minutes which will cover the entire procedure for setting up the brachytherapy device. In order to optimize the distractive potential of virtual reality, four different virtual reality programs will be offered to patients during each brachytherapy fraction. These programs will be contemplative so as not to compromise the immobility of the patients during the installation of the brachytherapy applicator.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Virtual Reality Helmet
Description: The radiotherapists can freely dialogue with the patients during the brachytherapy applicator' seating up, as in current practice.
Study: NCT02981693

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root canal sealer
Description: Patients who required root canal therapy were enrolled and allotted into either iRoot SP arm or AH Plus arm randomly.For Test Arm: iRoot SP was used as a sealer. Obturation was performed with Gutta-percha cones and root canal sealer by continuous-wave condensation technique. For Control Arm: AH Plus was used as root canal sealer. The same steps were followed for obturation as in Test Arm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root canal sealer
Description: Patients who required root canal therapy were enrolled and allotted into either iRoot SP arm or AH Plus arm randomly.For Test Arm: iRoot SP was used as a sealer. Obturation was performed with Gutta-percha cones and root canal sealer by continuous-wave condensation technique. For Control Arm: AH Plus was used as root canal sealer. The same steps were followed for obturation as in Test Arm.
Study: NCT01536509

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Behavioral Treatment (TBT)
Description: Families in the TBT condition will receive three individually-tailored behavioral intervention sessions in addition to the online education intervention with 1) guided problem-solving and behavior management training tailored to the unique needs and/or barriers of the family, and 2) discussion of the patient's adherence since the previous session. In addition, patients in the TBT condition will be signed up for text message reminder service offered free of charge via www.mymedschedule.com. These are generic reminder text messages are used to assist with adherence in adolescents. Intervention sessions will be conducted via telehealth delivery with trained postdoctoral psychology fellows or masters-level graduates using webcams, supplied by the study, and SkypeTM free software.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Only (EO)
Description: Families in the EO condition will receive three individual sessions in addition to the online education intervention to review 1) online educational intervention material to answer questions participants have, 2) educational brochures from the Crohn's and Colitis Foundation of America (CCFA), which contain additional information (e.g., Guide for Parents, Living with IBD, Guide for Kids and Teenagers), and 3) general healthy lifestyle recommendations (e.g., sleep, exercise, etc.). Sessions will be conducted via telehealth delivery with trained postdoctoral clinical psychology fellows or masters-level graduates using webcams, supplied by the study, and SkypeTM free software.
Study: NCT01290731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: 100-mg capsule once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon (pegIFN alpha-2a)
Description: 180 mcg injected subcutaneously (by a syringe under the skin) once weekly for 12 to 36 weeks (or until Week 48).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: 200-mg tablets (daily dose: 600-1000 mg) taken orally (by mouth) two times a day for 12 to 36 weeks (or until Week 48).
Study: NCT03390192

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual-mode stimulation
Description: 1Hz rTMS over contralesional primary motor cortex and anodal tDCS over ipsilesional primary motor cortex are simultaneously simulated.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single sham stimulation
Description: 1Hz rTMS over contralesional primary motor cortex and sham tDCS (no stimulation) over ipsilesional primary motor cortex are simultaneously simulated.
Study: NCT00601107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxercalciferol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxercalciferol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxercalciferol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04935294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Oral tablet.
Study: NCT02868528

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: chromosome screening with NGS technology
Study: NCT01941056

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: multi-CMV epitope modified vaccinia Ankara vaccine
Description: Given IM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02181738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Specified dose on specified days
Study: NCT02083211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mAb Nimotuzumab
Description: This group will receive a dose of 200 mg mAb hR3 (weekly over 18 weeks) plus chemotherapy (6 cycles every 21 days of Cisplatin (CDDP) 50 mg/m2 on day 1/, Vinorelbine 30 mg/m2 on day 1 and day 8)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group will receive a placebo in addition to chemotherapy in a similar regimen. Once the chemotherapy is completed a maintenance dose will be administered with 200 mg/dose of mAb hR3 every 14 days until progression.
Study: NCT05472298

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-management intervention
Description: lifestyle modification, goal setting, coaching and peer support, problem-solving
Study: NCT02794779

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Intravenous bolus infusion of oxytocin 3UI followed by re-asessment of uterine tone by obstetrician after 3 minutes. Infusion stops when uterine tone is adequate and is repeated if inadequate to the maximum of 9UI (3 bolus infusions). If uretine tone is inadequate after 9UI then other methods for preventing bleeding will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Intravenous bolus infusion of oxytocin 3UI followed by re-asessment of uterine tone by obstetrician after 3 minutes. Infusion stops when uterine tone is adequate and is repeated if inadequate to the maximum of 9UI (3 bolus infusions). If uretine tone is inadequate after 9UI then other methods for preventing bleeding will be used.
Study: NCT01149538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choline bitartrate
Description: Choline bitartrate 500 mg. daily, administered in fruit-flavored drink mix.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for choline bitartrate
Description: Placebo for choline bitartrate, administered daily in fruit-flavored drink mix.
Study: NCT00837447

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee replacement with NexGen CR knee prosthesis
Description: comparison of functional outcome in patients receiving either NexGen posterior cruciate-retaining or a high-flexion posterior cruciate-retaining total knee prosthesis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee replacement(TKR) with Nexgen CR-flex
Description: TKR using Nexgen CR-flex implant
Study: NCT00601237

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV-related text messaging
Description: Participants will receive up to 90 text messages related to abstinence, monogamy, and condom use over 3 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition-related text messaging
Description: Participants will receive up to 30 text messages about nutrition and healthy eating over 3 months.
Study: NCT03148639

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Avatar therapy
Description: Patients will receive 6 sessions of avatar therapy consisting of 45 minute (1 session per week). The therapy will consist in prompting patients to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the character of the avatar will progressively become under patients' control. More precisely, the avatar's speech and tone will gradually be changed by the therapist to echo patients' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce patients' feeling of empowerment over their voices.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Avatar therapy
Description: Patients will receive 6 sessions of avatar therapy consisting of 45 minute (1 session per week). The therapy will consist in prompting patients to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the character of the avatar will progressively become under patients' control. More precisely, the avatar's speech and tone will gradually be changed by the therapist to echo patients' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce patients' feeling of empowerment over their voices.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment-as-usual
Description: Treatment as usual will consist of typical or atypical antipsychotic medication and regulars appointments with psychiatrists and others care team members for a period of 6 weeks.
Study: NCT00140114

Intervention type: DRUG
Group type: OTHER
Intervention: Misoprostol (Cytotec®)
Description: 50 micrograms of sublingual or vaginal misoprostol every 4 hours for a maximum of 5 doses

Intervention type: DRUG
Group type: OTHER
Intervention: Misoprostol (Cytotec®)
Description: 50 micrograms of sublingual or vaginal misoprostol every 4 hours for a maximum of 5 doses
Study: NCT04710433

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive Neuromodulation
Description: Sacral nerve stimulation via two adhesive electrodes (single current).

Intervention type: OTHER
Group type: OTHER
Intervention: Medical and Behavioral Therapy
Description: Behavioral Therapy consists of toilet training, an active and healthy lifestyle. Doses of medical options are applied weight-adjusted.
Study: NCT03707730

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AGY
Description: oral AGY taken prior to meals

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral placebo taken prior to meals
Study: NCT02763995

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care
Description: This is a quasi-experimental study and the same group will be evaluated before and after the follow up.
Study: NCT01363076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: Single IN dose of 15 mg ketorolac tromethamine for subjects weighing \<50 kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: Single IN dose of 30 mg ketorolac tromethamine for subjects weighing ≥50 kg.
Study: NCT01769872

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Adipose Tissue derived MSCs Transplantation
Description: Intravenous injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 2x10e8 cells / 20mL Intrathecal injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 5x10e7 cells / 2mL Into a spinal cord injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 2x10e7 cells / 1mL
Study: NCT02130011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: with feeding/fluid instruction
Description: No additional intervention besides standard treatment prescription will be added. Investigators foresee daily kV cone beam CT matching (already standard in house). this subgroup of 10 patients will be asked not to eat or drink carbonated fluids three hours before CT simulation and daily treatment
Study: NCT04483947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2693
Description: Subcutaneous administration of AZD2693 multiple ascending doses in participants with NASH and who are carriers of the PNPLA3 148M risk allele(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2693
Description: Subcutaneous administration of AZD2693 multiple ascending doses in participants with NASH and who are carriers of the PNPLA3 148M risk allele(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2693
Description: Subcutaneous administration of AZD2693 multiple ascending doses in participants with NASH and who are carriers of the PNPLA3 148M risk allele(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2693
Description: Subcutaneous administration of AZD2693 multiple ascending doses in participants with NASH and who are carriers of the PNPLA3 148M risk allele(s).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants randomised to placebo will receive the corresponding dose volume of solution as participants receiving AZD2693 within the same cohort

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants randomised to placebo will receive the corresponding dose volume of solution as participants receiving AZD2693 within the same cohort

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants randomised to placebo will receive the corresponding dose volume of solution as participants receiving AZD2693 within the same cohort

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants randomised to placebo will receive the corresponding dose volume of solution as participants receiving AZD2693 within the same cohort
Study: NCT03408145

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Description: Injection of 3x 2.5ml of Hyaluronic Acid

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Description: Injection of 3x 2.5ml of Hyaluronic Acid

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amniotic Tissue Allograft
Description: Injection of 1x 1ml of Amniotic Tissue Allograft

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Amniotic Tissue Allograft
Description: Injection of 1x 1ml of Amniotic Tissue Allograft

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Injection of Saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Injection of Saline
Study: NCT00007501

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varicella-zoster vaccine
Description: Immunization with 0.5 ml, live, attenuated (Oka/Merck) varicella-zoster vaccine.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vaccine
Study: NCT00179179

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nutritional supplementation
Description: 2 oral ingestions per study visit of protein supplement containing a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat; 6 study visits over a 12-month period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nutritional supplementation
Description: 2 oral ingestions per study visit of protein supplement containing a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat; 6 study visits over a 12-month period

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: resistance training on a duel leg press consisting of 3 sets of 8-12 repetitions; the first 5 study visits over a 12-month period
Study: NCT01944332

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gamete treatment
Description: Patient specimen will be selected through a synthetic, sterile, single-use, culture-tested mesh. The specimen will then be placed in a 37°C environment. After 30 minutes, the selected portion is retrieved from the other side of the mesh. The spermatozoa will be prepared in the standard fashion and utilized for injection or intrauterine insemination after exposure to a membrane permeabilizing agent. Human recombinant PLC-zeta will also be used if the spermatozoa have been confirmed to be PLC-zeta deficient. The injected oocytes will then be exposed to activating agents for the purpose of inducing embryo development. The oocyte activating agent is calcium ionophore and for sperm membrane permeabilization to assist in sperm DNA decondensation is streptolysin O (SLO).
Study: NCT01194700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide 250(8puffs) via Evohaler actuator
Description: 8 puffs of Seretide250/Placebo via Evohaler actuator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide 250(8puffs) via Evohaler actuator
Description: 8 puffs of Seretide250/Placebo via Evohaler actuator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide 250(8puffs) via Evohaler actuator
Description: 8 puffs of Seretide250/Placebo via Evohaler actuator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide 250(8puffs) via Evohaler actuator
Description: 8 puffs of Seretide250/Placebo via Evohaler actuator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide 250 (8 puffs)/placebo via Volumatic spacer
Description: 8 puffs of Seretide 250/placebo via volumatic spacer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide 250 (8 puffs)/placebo via Volumatic spacer
Description: 8 puffs of Seretide 250/placebo via volumatic spacer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide 250 (8 puffs)/placebo via Volumatic spacer
Description: 8 puffs of Seretide 250/placebo via volumatic spacer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide 250 (8 puffs)/placebo via Volumatic spacer
Description: 8 puffs of Seretide 250/placebo via volumatic spacer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide 250/placebo 8 puffs via Aerochamber Plus spacer
Description: Seretide 250/placebo 8 puffs via Aerochamber Plus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide 250/placebo 8 puffs via Aerochamber Plus spacer
Description: Seretide 250/placebo 8 puffs via Aerochamber Plus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide 250/placebo 8 puffs via Aerochamber Plus spacer
Description: Seretide 250/placebo 8 puffs via Aerochamber Plus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide 250/placebo 8 puffs via Aerochamber Plus spacer
Description: Seretide 250/placebo 8 puffs via Aerochamber Plus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide 250/placebo via Synchro-Breathe
Description: Seretide 250/placebo 8puffs via breath actuated Synchro-Breathe device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide 250/placebo via Synchro-Breathe
Description: Seretide 250/placebo 8puffs via breath actuated Synchro-Breathe device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide 250/placebo via Synchro-Breathe
Description: Seretide 250/placebo 8puffs via breath actuated Synchro-Breathe device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide 250/placebo via Synchro-Breathe
Description: Seretide 250/placebo 8puffs via breath actuated Synchro-Breathe device
Study: NCT00791882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Skills Training
Description: A program developed during 20 weeks according to adapted BELLACK 's manual (1997),including sessions in group one hour per week.

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Social Skills Training
Description: A program developed during 20 weeks according to adapted BELLACK 's manual (1997),including sessions in group one hour per week.
Study: NCT04565223

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia
Description: is a multicomponent intervention which focuses on cognitive and behavioral factors that contribute to sleep disorders , The CBT-i included sleep hygiene counseling, stimulus control, cognitive restructuring, relaxation techniques, and benzodiazepine therapy or withdrawal (when needed). To conduct the intervention, guidelines for GPs and nurses and graphic and written materials for patients (sleep diary, registry of behavior habits, and cognitive problems) were developed